UAE and US-based biotech startup BioSapien has extended its pre-Series A round to $7 million with new investment from Golden Gate Ventures’ MENA Fund, marking the fund’s first investment in the region, it announced in a statement today. The extension follows the company’s initial $5.5 million raise in December led by Global Ventures, with participation from Dara Holdings.

Founded in 2018 by Khatija Ali, BioSapien has developed MediChip, a 3D-printed drug delivery platform that enables localized cancer treatment with minimal systemic side effects. The startup plans to use the fresh funds to accelerate clinical trials in the UAE, which are set to begin in Q2 2025, along with product development and scaling manufacturing capabilities.

The company’s platform allows for targeted medication delivery directly to tumors, reducing the quantity of drugs needed while maintaining treatment effectiveness. Initially focusing on colorectal cancer patients, BioSapien plans to expand its technology to other cancers including pancreatic and lung cancer, as well as non-cancer applications such as opioids, hormones, and biologics.

Khatija Ali, CEO and Founder of BioSapien, said, “We are delighted to announce our new investment and are grateful for all the support we have received. The expertise and belief in our vision from our investors come at a critical juncture as we initiate clinical trials in Abu Dhabi.”

Michael Lints, Partner at Golden Gate Ventures MENA, commented, “Having met CEO and Founder Khatija at Hub71 in Abu Dhabi, we were instantly impressed by her passion and vision. This investment not only supports a groundbreaking technology but also reinforces the Gulf region’s role as a global leader in healthcare innovation.”

The startup aims to treat over one million patients by 2035 through its versatile technology, which can be adapted for various medical applications beyond cancer treatment.